Skip to main content

CytoDyn, Inc. (CYDY)

OTCMKTS: CYDY · Delayed Price · USD
2.20 0.19 (9.45%)
Sep 20, 2021 2:32 PM EDT - Market open
Market Cap1.43B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out632.59M
EPS (ttm)-0.26
PE Ration/a
Forward PE10.81
Dividendn/a
Ex-Dividend Daten/a
Volume5,549,226
Open2.04
Previous Close2.01
Day's Range1.97 - 2.38
52-Week Range1.25 - 7.40
Beta-0.59
Analystsn/a
Price Target4.00 (+81.8%)
Est. Earnings DateOct 5, 2021

About CYDY

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretrovi...

IndustryBiotechnology
Employees24
Stock ExchangeOTCMKTS
Ticker SymbolCYDY
Full Company Profile

Financial Performance

Financial Statements

News

Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now

Penny stocks bouncing back after the stock market sell-off The post Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols:BESTVRPX
20 hours ago - PennyStocks

CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group

VANCOUVER, Wash.--(BUSINESS WIRE)--The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antag...

20 hours ago - Business Wire

Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director cand...

3 days ago - Business Wire

Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of CytoDyn Inc. (OTCQB:CYDY) concerning the Company and its directors' and officers' possible violations of sta...

5 days ago - Business Wire

CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the po...

1 week ago - GlobeNewsWire

CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Se...

An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients)

1 week ago - GlobeNewsWire

Group of CytoDyn Stockolders Responds to Misleading Company News Release

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY” or the “Company”) (OTC: CYDY) that has nominated five highly experienced director can...

1 week ago - Business Wire

CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 ...

VANCOUVER, Washington, Sept. 02, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the p...

2 weeks ago - GlobeNewsWire

CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws

VANCOUVER, Wash.--(BUSINESS WIRE)--The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antag...

2 weeks ago - Business Wire

Group of CytoDyn Stockholders Warns Stockholders of Board's Continued Value Destruction and Failures

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Group”) of CytoDyn Inc. (“CYDY” or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve o...

2 weeks ago - Business Wire

CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs

Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the...

3 weeks ago - GlobeNewsWire

Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director N...

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Group”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on ...

3 weeks ago - Business Wire

CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group

VANCOUVER, Wash.--(BUSINESS WIRE)--The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antag...

3 weeks ago - Business Wire

Best Biotech Penny Stocks to Buy Right Now? 3 to Watch Next Month

Biotech penny stocks are heating up right now, here's 3 for next month's watchlist The post Best Biotech Penny Stocks to Buy Right Now? 3 to Watch Next Month appeared first on Penny Stocks to Buy, Picks...

Other symbols:JAGXNMTR
1 month ago - PennyStocks

Group of CytoDyn Stockholders Responds to Highly Misleading Company Release

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) that has nominated five highly experienced director candi...

1 month ago - Business Wire

CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation

VANCOUVER, Wash.--(BUSINESS WIRE)--The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antag...

1 month ago - Business Wire

CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report

Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission

1 month ago - GlobeNewsWire

CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful P...

VANCOUVER, Washington--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company, today announced that it has filed a lawsuit in the United States Dist...

1 month ago - Business Wire

CytoDyn Receives Clearance from Brazil's ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

VANCOUVER, Washington--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multip...

1 month ago - Business Wire

CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid

VANCOUVER, Washington--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company, announced today that the director nominations submitted by an activis...

1 month ago - Business Wire

Large shareholder group calls for a board overhaul at pharma company CytoDyn

Paul Rosenbaum, CEO of SWR Corp., is no stranger to shareholder activism. He's leading a group of investors calling for change at CytoDyn.

1 month ago - CNBC

CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials

VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the po...

2 months ago - GlobeNewsWire

CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Dose...

CytoDyn will seek FDA guidance on proceeding with an expedited regulatory plan for approval of leronlimab with existing FDA Fast Track designation for mTNBC CytoDyn will seek FDA guidance on proceeding ...

2 months ago - GlobeNewsWire

CytoDyn's Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosag...

CytoDyn anticipates preliminary efficacy data regarding potential responders in metastatic triple-negative breast cancer in approximately two weeks

2 months ago - GlobeNewsWire

3 Biotechs to Avoid Like the Plague in July

Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.

Other symbols:CVMNWBO
2 months ago - The Motley Fool